Clinical Trial

MAX - SHOCK Clinical Trial

Study acronym: MAX-SHOCK
Recruiting
View on ClinicalTrials.gov →
Summary
Can Electrical Cardioversion (ECV) for AF be improved. It is the preferred method to restore sinus rhythm in patients with AF in whom a rhythm-control strategy is pursued. Hypothesis: ECV success rates will be greater with a biphasic defibrillator with maximum energy of 360J (® Physio-Control) compared to a biphasic defibrillator with maximum energy of 200J (® Zoll)
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2024-08-14; most recent amendment 2026-01-30.
Status change: Not Yet Recruiting → Recruiting 2025-08-13
Trial Details
NCT Number NCT06556667
Lead Sponsor Ottawa Heart Institute Research Corporation
Conditions Cardioversion, Atrial Fibrillation
Enrollment 376 participants
Start Date 2025-03-31
Primary Completion 2027-09-01 (estimated)
Study Completion 2027-09-01 (estimated)
Updated on ClinicalTrials.gov 2026-02-03